Paget's disease of bone treated in five days with AHPrBP (APD) per Os
作者:
D. Thiébaud,
P. Jaeger,
P. Burckhardt,
期刊:
Journal of Bone and Mineral Research
(WILEY Available online 1987)
卷期:
Volume 2,
issue 1
页码: 45-52
ISSN:0884-0431
年代: 1987
DOI:10.1002/jbmr.5650020108
出版商: John Wiley and Sons and The American Society for Bone and Mineral Research (ASBMR)
数据来源: WILEY
摘要:
AbstractAmino‐hydroxypropylidene bisphosphonic acid (AHPrBP, previously APD) is a potent inhibitor of bone resorption. Since it remains in bone for a long time, and since it was not found to impair bone mineralization, it could be administered at high dose over a short period of time. Therefore, 11 patients with symptomatic Paget's disease received AHPrBP orally at 1200 mg/day over 5 consecutive days. Controls were performed after 1 month in all patients, 6 months in 8 patients, and one year in 4 patients. Clinical improvement and biochemical remission was observed in all patients, except one with severe disease.Side effects were negligible. Disease activity at bone scintigram decreased over 6 months. Plasma alkaline phosphatase activity fell progressively and significantly from 210 ± 26 U/I (x̄ ± SEM) to 103 ± 10 U/I after 6 months (nl<120 U/I).Urinary excretion of hydroxyproline decreased immediately and became normal (nl<2.3 μmol/IGF) as a mean at day 5 (from 4.6 ± 0.4 μmol/IGF to 2.1 ± 0.3 μmol/IGF). Thereafter it remained within the normal range (2.0 ± 0.2 μmol/l at day 180). Plasma calcium and phosphate concentrations fell transiently between day 4 and 15, whereas plasma PTH levels increased over this period of time. In conclusion, a short course of AHPrBP given per os at high dose induces a rapid decline in activity and remission of moderate Paget's disease, without significant
点击下载:
PDF
(1148KB)
返 回